5Sequra S, Romero D, Carrera C, et al. Kaposi' s varicelliform eruption during treatment of atopic dermatitis with pimecrolimus cream [ J ]. Acta Derm Venereol, 2005,85 ( 6 ) :524-525.
6Lanier R,Trost L,Tippin T, et al. Development of CMX001 for the treatment of poxvirus infections[ J~. Viruses,2010,2(2) :2740-2762.
7Abreu-Velez AM, Klein AD, Howard MS. Junctional adhesion molecule overexpression in Kaposi varicelliform eruption skin lesions-as a possi- ble herpes virus entry site[J]. N Am J Mad Sci,2010,2(9) :35-41.
8Helen SP, Mark M, George A, et al. Pharmacokinetics and safety of FV-100 ,a novel oral anti-herpes zoster nucleoside analogue, adminis- tered in single and multiple doses to healthy young adult and elderly adult volunteers [ J ]. Antimicrob Agents Chemother, 2011,55 ( 6 ) : 2847-2854.
9Chono K, Katsumata K, Kontani T, et al. ASP2151, a novel helicase- primase inhibitor, possesses antiviral activity against varicella-zoster vi- rus and herpes simplex virus types 1 and 2 [ J ]. J Antimicrob Che- mother,2010,65 ( 8 ) : 1733-1741.
